Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion

news.law April 21, 2026

Eli Lilly entered a definitive agreement to acquire Kelonia Therapeutics for upwards of $7 billion.

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader population of cancer patients and also eliminate the complex and costly manufacturing process required by current approaches.

Nexstar-Tegna TV Station Merger Blocked Until Antitrust Lawsuit is Settled

PPG to Acquire Ozark Materials for $65 Million